Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.48 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | TEK | Q02763 | 2/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049967 | 0.90 | EGFR (0.58) | EGFRERBB2RAF1FGFR2FLT4 | |
| SCHEMBL15050542 | 0.87 | EGFR (0.53) | EGFRERBB2RAF1FGFR2FLT4 | |
| SCHEMBL15050663 | 0.87 | CYP3A4 (0.57) | EGFRERBB2RAF1FGFR2FLT4 | |
| SCHEMBL15050662 | 0.87 | CYP3A4 (0.57) | EGFRERBB2RAF1FGFR2FLT4 | |
| SCHEMBL173309 | 0.86 | EGFR (0.48) | EGFRERBB2RAF1FGFR2FLT4 | |
| SCHEMBL15050150 | 0.81 | CYP3A4 (0.55) | EGFRERBB2RAF1FGFR2FLT4 | |
| SCHEMBL15050378 | 0.80 | CYP3A4 (0.60) | EGFRERBB2RAF1FGFR2FLT4 | |
| SCHEMBL15050622 | 0.78 | CYP3A4 (0.57) | EGFRERBB2RAF1FGFR2FLT4 | |
| SCHEMBL15050619 | 0.78 | CYP3A4 (0.57) | EGFRERBB2RAF1FGFR2FLT4 | |
| SCHEMBL176336 | 0.78 | EGFR (0.50) | EGFRERBB2RAF1FGFR2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611797-B1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO LTD (KR) | 2016-12-28 | — | — | EP | disclosed |
| US-8835458-B2 | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | HANMI SCIENCE CO., LTD (KR) | 2014-09-16 | — | — | US | disclosed |
| EP-2611797-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | Hanmi Science Co., Ltd. (KR) | 2013-07-10 | — | — | EP | disclosed |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO., LTD (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012030160-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI HOLDINGS CO., LTD. (KR) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | CASP7, API5, BAX | EGFR 4690/4885ERBB2 4805/4885RAF1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.